Drugs / MURIZATOCLAX
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Clinical hold | Other | — | — | 2019-09-12 | “The Phase 1 dose escalation clinical trial for AMG 397 ( NCT03465540 ) is on a clinical hold to evaluate a safety signal for cardiac toxicity.” amgen.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03465540 | Aug 2018 → Jul 2019 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, plasma cell myeloma | Amgen | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-12 | Amgen | Regulatory Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 amgen.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-09-12 | Amgen | Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 amgen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MURIZATOCLAX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650225 ↗ |
| Known as | AMG 397 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03465540 ↗ |
| Modality | Small molecule | — CHEMBL4650225 ↗ |
| Route | Oral | “AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.” NCT03465540 ↗ |